Literature DB >> 26255026

Cx43 increases serum induced filopodia formation via activation of p21-activated protein kinase 1.

Petra Kameritsch1, Felizitas Kiemer2, Heike Beck3, Ulrich Pohl4, Kristin Pogoda5.   

Abstract

In a previous study we could show that connexin 43 (Cx43) expression increased the migration of cells in a channel-independent manner involving the MAPK p38. We analyzed here the mechanism by which Cx43 enhanced p38 activation and migration related changes of the actin cytoskeleton. HeLa cells were used as a model system for the controlled expression of Cx43 and truncated Cx43 proteins. The expression of Cx43 altered the actin cytoskeleton organization in response to serum stimulation. Cx43 expressing HeLa cells had significantly more filopodial protrusions per cell than empty-vector transfected control cells. The expression of the channel incompetent carboxyl tail of Cx43 was sufficient to enhance the filopodia formation whereas the N-terminal, channel-building part, had no such effect. The enhanced filopodia formation was p38 dependent since the p38 blocker SB203580 significantly diminished it. Immunoprecipitation revealed an interaction of the upstream regulator of p38, p21-activated protein kinase 1 (PAK1), with Cx43 resulting in an enhanced phosphorylation of PAK1. Moreover, p38 activation, filopodia formation and cell migration were significantly reduced by blocking the PAK1 activity with its pharmacological inhibitor, IPA-3. The p38 target Hsp27, which favors the actin polymerization in its phosphorylated form, was significantly more phosphorylated characterizing it as a potential candidate molecule to enhance the serum-induced actin polymerization in Cx43 expressing cells. Our results provide a novel mechanism by which Cx43 can modify actin cytoskeletal dynamics and may thereby enhance cell migration.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Actin cytoskeleton; Connexin; Gap junction independent; Migration; p38

Mesh:

Substances:

Year:  2015        PMID: 26255026     DOI: 10.1016/j.bbamcr.2015.08.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Gap junction protein connexin43 and tunneling nanotubes in human trabecular meshwork cells.

Authors:  Xinbo Li
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-10-15

2.  GJA1-20k Arranges Actin to Guide Cx43 Delivery to Cardiac Intercalated Discs.

Authors:  Wassim A Basheer; Shaohua Xiao; Irina Epifantseva; Ying Fu; Andre G Kleber; TingTing Hong; Robin M Shaw
Journal:  Circ Res       Date:  2017-09-18       Impact factor: 17.367

3.  The Cx43 Carboxyl-Terminal Mimetic Peptide αCT1 Protects Endothelial Barrier Function in a ZO1 Binding-Competent Manner.

Authors:  Randy E Strauss; Louisa Mezache; Rengasayee Veeraraghavan; Robert G Gourdie
Journal:  Biomolecules       Date:  2021-08-12

Review 4.  Connexins in cancer: bridging the gap to the clinic.

Authors:  Trond Aasen; Edward Leithe; Sheila V Graham; Petra Kameritsch; María D Mayán; Marc Mesnil; Kristin Pogoda; Arantxa Tabernero
Journal:  Oncogene       Date:  2019-02-27       Impact factor: 9.867

Review 5.  Cx43 and the Actin Cytoskeleton: Novel Roles and Implications for Cell-Cell Junction-Based Barrier Function Regulation.

Authors:  Randy E Strauss; Robert G Gourdie
Journal:  Biomolecules       Date:  2020-12-10

6.  Cx43 Promotes Endothelial Cell Migration and Angiogenesis via the Tyrosine Phosphatase SHP-2.

Authors:  Hanna Mannell; Petra Kameritsch; Heike Beck; Alexander Pfeifer; Ulrich Pohl; Kristin Pogoda
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

7.  α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway.

Authors:  Marine Angé; Diego Castanares-Zapatero; Julien De Poortere; Cécile Dufeys; Guillaume E Courtoy; Caroline Bouzin; Rozenn Quarck; Luc Bertrand; Christophe Beauloye; Sandrine Horman
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.